UNSPSC 51294420: Oxypertine hydrochloride

This classification denotes a dopamine antagonist C23H29N3O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9P131473P6, chemically known as 1h-indole, 5,6-dimethoxy-2-methyl-3-(2-(4-phenyl-1-piperazinyl)ethyl)-, hydrochloride (1:1), but more generally known as oxypertine hydrochloride, which bears US NIH Compound Identifier 24194514. European Medicines Agency schedules Oxypertine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03592MIG.

Most nations, for tariff and trade purposes, schedule oxypertine hydrochloride under HS 29335995 and SITC 51576. As of Q4 2014, OXYPERTINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC1C(C2CC(C(CC2[NH]1)OC)OC)CCN3CCN(CC3)C4CCCCC4.CL.

UNSPSC 51294420 Oxypertine hydrochloride is a Commodity code that in recent state and local procurement activity maps poorly to the specific active pharmaceutical ingredient named. The three recent opportunities posted under or near this code—Seminole County's naloxone and drug deactivation systems procurement, the Texas HHS Commission's therapeutic pharmacy initiative direct-to-manufacturer RFI, and the Minnesota Multistate Cooperative Purchasing Alliance's generic multi-source pharmaceuticals RFP—involve finished pharmaceutical products, wholesale distribution relationships, and pharmacy benefit program design rather than oxypertine hydrochloride specifically. State and local agencies using this code are acquiring finished drugs, OTC products, and pharmacy supply-chain services for community health programs, correctional facilities, state employee health plans, and other public-health missions; the code itself appears to capture pharmaceutical commodities more broadly than its nominal title suggests.

Activity under the code spans county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multi-state cooperative purchasing consortia (Minnesota MMCAP, which includes participating Oregon jurisdictions). Seminole County's IFB60459723LAS, posted June 30, 2026 with a response deadline of July 26, 2023, seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries. The Texas HHS Commission's RFI HHS0017013, posted April 3, 2026, addresses direct-to-manufacturer prescription contracting strategies rather than a specific commodity purchase. MMCAP's RFP S1070000015802, posted January 20, 2026 with a March 26, 2026 response deadline, establishes multiple contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson) across Minnesota and Oregon, with awards effective July 1, 2026 and a two-year contract term. The code shows recent activity concentrated in the South and Midwest, though the scope mismatch between the code's name and actual procurement content suggests potential data-classification drift within state procurement systems.